Skip to content

Efficacy of a new cost effective implant used in treatment of patients with refractory glaucoma.

Comparative efficacy of Aurolab Aqueous drainage implant vs Ahmed Glaucoma valve in patients with refractory glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/07/009089
Enrollment
38
Registered
2017-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Refractory Glaucoma patients

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Training Branch
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: IOP >=18 mm of Hg with significant optic nerve damage and visual field loss, which had not responded to maximum tolerated conventional antiglaucoma medications/laser or surgical treatment or Uncontrolled glaucoma with prior history of Filtering surgery/ Uveitic/ Neovascular/ Secondary glaucoma (Pseudophakia/ Aphakia/ Penetrating keratoplasty/ Vitrectomy/Iridocorneal endothelial syndrome associated glaucoma)/ Developmental glaucoma, considered at high risk of failure/ complication following conventional filtering surgery e.g. significant conjunctival scarring or active neovascular glaucoma

Exclusion criteria

Exclusion criteria: Younger than 18 years Absent light perception History of previous cyclodestructive procedure/ aqueous shunt Uncontrolled glaucoma expected to have favorable post-operative outcome by conventional trabeculectomy Corneal abnormalities that precluded accurate IOP readings Active ocular disease (e.g. active uveitis, ocular infection) Uncontrolled systemic diseases.

Design outcomes

Primary

MeasureTime frame
Intraocular pressure (IOP) and anti-glaucoma medications requiredTimepoint: Day1, week 1, month 1, month 3, month 6

Secondary

MeasureTime frame
Visual acuity, Visual field, Postoperative complications and interventions. Complete success was defined as IOP between 5 mmHg to 18 mmHg without anti-glaucoma medications, without any vision threatening complications or additional glaucoma surgery or laser procedures.Timepoint: Day1, week 1, month 1, month 3, month 6

Countries

India

Contacts

Public ContactDr Surinder Singh Pandav

PGIMER

sspandav@yahoo.com9876644007

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026